Vienna-based
Flinn, a provider of AI-powered software designed to automate regulatory and
quality processes in medtech, has raised $20 million in additional funding. The
round was led by HV Capital, with participation from US-based healthcare
investor BHI – Bertelsmann Healthcare Investments, alongside continued support
from existing investors Cherry Ventures, Speedinvest, and SquareOne.
The
funding comes as healthcare systems globally face increasing pressure from
ageing populations, more complex treatment approaches, and administrative
challenges that are placing strain on public healthcare budgets. As costs rise,
governments face growing difficulty managing expenditure, while patients may
encounter reduced access to new treatments or higher out-of-pocket costs.
Medical
devices and pharmaceuticals can improve efficiency through areas such as
automated healthcare, advanced diagnostics, and personalised treatments.
However, innovation in these sectors is shaped by strict regulatory and quality
frameworks.
While
these requirements are essential for patient safety, they can also extend
development timelines and increase the costs of bringing products to market and
maintaining compliance throughout their lifecycle. As compliance demands grow,
many companies face rising operational complexity in managing regulatory and
quality processes.
Flinn
aims to address these challenges through AI-based software that automates
regulatory workflows, data evaluation, and reporting, replacing manual,
document-heavy processes with more scalable systems.
Bastian Krapinger-Rüther, Co-founder and Co-CEO of Flinn, said regulatory and quality
requirements are increasingly contributing to costs across the medical product
lifecycle.
Our software replaces manual, document-heavy workflows with
automated systems that scale across products, markets, and regulatory regimes.
This additional investment enables us to extend that infrastructure across more
lifecycle stages and support manufacturers operating globally,
he added.
By
integrating automation into regulatory and quality functions, the platform aims
to help manufacturers improve operational efficiency, shorten development
timelines, and maintain compliance while supporting patient safety
requirements. The approach is intended to reduce administrative burden and
allow teams to focus more on product development and innovation.
With
the new funding, Flinn plans to expand its platform beyond existing regulatory
and post-market solutions to cover earlier development stages as well as
commercial processes, creating a unified compliance and quality framework
across the full medical product lifecycle. The company also plans to use the
funding to support international growth, including further expansion across
Europe and entry into the US market.